产品说明书

Cyclophosphamide

Print
Chemical Structure| 50-18-0 同义名 : -
CAS号 : 50-18-0
货号 : A545946
分子式 : C7H15Cl2N2O2P
纯度 : 98%
分子量 : 261.08
MDL号 : MFCD00005978
存储条件：

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 40 mg/mL(153.21 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 30 mg/mL(114.9 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 Cyclofosphamide is a potent immunosuppressive agent and the most commonly used drug in blood and marrow transplantation. Cyclophosphamide's unique metabolism and inactivation by aldehyde dehydrogenase is responsible for its distinct cytotoxic properties[3]. High-dose chemotherapy and continuous daily oral regimens are associated with significant toxicity profiles, but i.v. pulsed regimens have lowered the rates of adverse effects in rheumatological studies[4]. In haploidentical hematopoietic stem cell transplants, post-transplant cyclophosphamide together with standard prophylaxis reduces the incidence of GVHD (graft-versus-host disease) to acceptable rates without the need for T cell depletion[5]. Moreover, using in vitro rodent embryo culture has demonstrated that Cyclofosphamide must be bioactivated to be teratogenic[6]. High-dose cyclophosphamide (200 mg/kg) can as a conditioning regimen for allogeneic bone marrow transplantation. High-dose cyclophosphamide is maximally immunosuppressive, but not myeloablative. Early hematopoietic stem cells are spared the cytotoxicity of cyclophosphamide because of their high levels of aldehyde dehydrogenase, an enzyme that confers resistance to the drug[7].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.83mL

0.77mL

0.38mL

19.15mL

3.83mL

1.92mL

38.30mL

7.66mL

3.83mL
参考文献

[1]Schwartz PS, Waxman DJ. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol. 2001 Dec;60(6):1268-79.

[2]al-Jafari AA, Duhaiman AS, et al. Inhibition of human acetylcholinesterase by cyclophosphamide. Toxicology. 1995 Jan 19;96(1):1-6.

[3]Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009 Nov;6(11):638-47

[4]Kim J, Chan JJ. Cyclophosphamide in dermatology. Australas J Dermatol. 2017 Feb;58(1):5-17

[5]Al-Homsi AS, Roy TS, Cole K, Feng Y, Duffner U. Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant. 2015 Apr;21(4):604-11

[6]Mirkes PE. Cyclophosphamide teratogenesis: a review. Teratog Carcinog Mutagen. 1985;5(2):75-88

[7]Brodsky RA. High dose cyclophosphamide treatment for autoimmune disorders. ScientificWorldJournal. 2002 Jun 28;2:1808-15